

Research Article

MicroRNA-9 Enhanced Cisplatin Sensitivity in Nonsmall Cell Lung Cancer Cells by Regulating Eukaryotic Translation Initiation Factor 5A2

Qiaoling Pan, Lebo Sun, Dawei Zheng, Ni Li, Huoshun Shi, Jie Song, Guofeng Shao , and Guodong Xu 

Department of Cardiothoracic Surgery, The Affiliated Hospital, Ningbo Medical Center Lihuli Hospital, Ningbo University, Ningbo, Zhejiang 315041, China

Correspondence should be addressed to Guofeng Shao; sgf1958@sina.com and Guodong Xu; 13616577156@163.com

Received 10 February 2018; Accepted 11 June 2018; Published 5 August 2018

Academic Editor: Xin-yuan Guan

Copyright © 2018 Qiaoling Pan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

We determined the role of microRNA (miR)-9 in regulating cisplatin chemoresistance in nonsmall cell lung cancer (NSCLC) cells. miR-9 and eukaryotic translation initiation factor 5A2 (eIF5A2) levels were examined by reverse transcription–quantitative PCR. Cell Counting Kit-8 and the 5-ethynyl-2'-deoxyuridine (EdU) assay were used to determine the effects of miR-9 mimic or inhibitor on NSCLC cell proliferation and viability, respectively. Bioinformatics was used to analyze the relationship between miR-9 and eIF5A2. Flow cytometry was used to analyze the percentage of apoptotic cells. miR-9 mimic enhanced cisplatin sensitivity, while miR-9 inhibitor produced the opposite result. eIF5A2 was identified as a potential target of miR-9, where miR-9 regulated eIF5A2 expression at mRNA and protein level. miR-9 mimic decreased the expression of eIF5A2 mRNA and protein, while miR-9 inhibitor increased eIF5A2 expression. eIF5A2 knockdown resolved the effects of miR-9 mimic or inhibitor on cisplatin sensitivity. miR-9 may be a potential biomarker for enhancing cisplatin sensitivity by regulating eIF5A2 in NSCLC cells.

1. Introduction

Lung cancer is one of the most common malignancies and is a leading cause of cancer-related death worldwide [1]. About 80% of lung cancer diagnosed is nonsmall cell lung cancer (NSCLC) [2]. Cisplatin is the most active chemotherapeutic agent against NSCLC; however, cisplatin resistance often occurs in clinical practice [3]. The process of cisplatin resistance is multifactorial and includes changes in drug accumulation and the apoptosis pathway, drug target interaction, and increased DNA repair [4]. The potential molecular mechanism of the development of cisplatin resistance remains unclear. Therefore, there is a greatly urgent need to identify novel molecules to overcome cisplatin resistance in NSCLC.

MicroRNAs (miRNAs) are small, noncoding, endogenous RNA molecules that play vital roles in gene expression by binding to the 3' untranslated region (3'UTR) of the target gene mRNA, leading to mRNA degradation or repression of translation [5]. MiRNAs are expressed in some human

cancers and play important roles in carcinogenesis [6]. Accumulating evidence has suggested that many differentially regulated miRNAs, such as miR-9, miR-30b, miR-7, and miR-139, are related to many cellular processes, e.g., cell proliferation, invasion and metastasis, differentiation, development, apoptosis, and the processes of drug resistance [7–11]. miR-9 was initially demonstrated to function in neurogenesis and is expressed at different levels in various human cancers. MiR-9 expression is decreased in ovarian cancer, gastric cancer, and oral squamous cell carcinoma, while its expression is increased in other cancers, such as colorectal cancer, breast cancer, and NSCLC [7, 12–16]. MiR-129 and miR-199a-3p overexpression enhance cisplatin sensitivity by targeting P-glycoprotein (P-gp) and downregulating TFAM (transcription factor A, mitochondrial) in human gastric cancer cells and breast cancer cells, respectively [17, 18]. These reports indicate that more in-depth research of miRNAs, which play important roles in cisplatin chemoresistance in NSCLC, is necessary.

In the present study, we investigated the role of miR-9 in cisplatin resistance and explored the mechanism of miR-9 in the expression of genes linked with cisplatin resistance. We found that miR-9 regulates eukaryotic translation initiation factor 5A2 (eIF5A2). Additionally, we confirmed that miR-9 overexpression enhances cisplatin sensitivity in NSCLC cells, while miR-9 inhibitor enhanced NSCLC cell cisplatin resistance. Our study reveals miR-9 as a novel target that may improve NSCLC treatment.

2. Materials and Methods

2.1. Cell Culture and Reagents. Human NSCLC cell lines (A549, NCI-H358, and NCI-H1299) were obtained from American Type Culture Collection (Manassas, VA, USA) and cultured in RPMI 1640 medium (Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS; Gibco) and 1% penicillin/streptomycin (Sigma, St. Louis, MO, USA). The cells were maintained at 37°C in a 5% CO₂ incubator. eIF5A2 small interfering RNA (siRNA) and negative control were purchased from Santa Cruz Biotechnology (Santa Cruz, Dallas, TX, USA). MiR-9 mimic and inhibitor were synthesized by GenePharma (Shanghai, China).

2.2. Cell Viability. Cell viability was measured using Cell Counting Kit-8 (CCK-8; Dojindo, Kumamoto, Japan). The NSCLC cells were seeded at a density of 3000 cells per well in 96-well plates with complete medium to grow in a 37°C incubator for 24 h. Then, the culture medium was replaced with medium containing 10% FBS and 0, 0.3125, 0.625, 1.25, 2.5, or 5 µg/mL cisplatin. After a 48-hour incubation, 10 µL CCK-8 solution was added and the cells were incubated for an additional 3 h. The absorbance at 450 nm was detected using an MRX II microplate reader (Dy nex Technologies, Chantilly, VA, USA). Relative cell viability was calculated as a percentage of untreated controls.

2.3. Transient Transfection with miR-9 Mimic and Inhibitor. The cells were seeded in 6-well plates (2×10^5 cells/well) and transfected with 100 nM miR-9 mimic, 100 nM miR-9 inhibitor, 100 nM eIF5A2 siRNA, or negative siRNA using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions.

2.4. Quantitative Reverse Transcription-PCR (RT-qPCR). Total RNA was extracted from the cells using TRIzol (Invitrogen) according to the manufacturer's instructions. The first-strand complementary DNA (cDNA) was synthesized using a PrimeScript RT Reagent kit (TaKaRa Biotechnology, Dalian, China), followed by PCR amplification in an ABI 7500 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) and SYBR Green dyestuff (TaKaRa Biotechnology) according to the manufacturers' instructions. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and U6 were used as internal controls. miR-9 and eIF5A2 expression were analyzed using the comparative threshold cycle ($2^{-\Delta\Delta Ct}$) method [19]. All experiments were repeated at least three times. The target genes were amplified using the following forward and reverse primers: eIF5A2

siRNA, 5'-GCAGACGAAAUUGAUUUCATT-3', and 5'-UGAAAUCAUUUCGUCUGCTT-3'; GAPDH, 5'-UGACCUCACUACAUGGUUTT-3', and 5'-AACCAUGUAGUUGAGGUCATT-3'; MIR9, 5'-TCTTTGGTTATCTAGCTGTATGA-3'; miR-9 mimic, 5'-UCUUUGGUUAUCUAGCUGUAUGA-3' and 5'-AUACAGCUAGAUAAACCAAAGAUU-3'; miR-9 inhibitor, 5'-UCAUACAGCUAGAUAAACCAAAGA-3'.

2.5. Western Blotting. Western blotting was used to determine the protein expression levels in the NSCLC cells. Total protein was extracted using cell lysis buffer (Cell Signaling Technology, Danvers, MA, USA) containing protease inhibitors (Sigma) and quantified using a bicinchoninic acid (BCA) protein assay kit (Beyotime Biotechnology, Shanghai, China). Proteins (40 µg/sample) were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), transferred to polyvinylidene difluoride (PVDF) membranes (Millipore, Billerica, MA, USA), and blocked with 5% defatted milk in Tris-buffered saline and 0.1% Tween 20 (TBS-T) at 37°C for 2 h. After washing three times, the membranes were incubated with primary antibody (eIF5A2, 1:1000 in TBS-T, Santa Cruz Biotechnology) at 4°C overnight. After washing three times, the membranes were incubated with the appropriate horseradish peroxidase-labeled secondary antibody (1:2000) at room temperature for 2 h. The protein bands were detected by chemiluminescence (GE Healthcare, Piscataway, NJ, USA). Data were quantified by the optical density of each band; GAPDH detection on the same membrane was used as the internal control.

2.6. 5-Ethynyl-2'-Deoxyuridine (EdU) Staining. Cell proliferation was examined using a Click-iT EdU Imaging Kit (Invitrogen) according to the manufacturer's instructions.

2.7. Flow Cytometry. NSCLC cells were transfected with miR-9 mimic, inhibitor, or negative control for 48 h and incubated for 48 h with cisplatin as follows: A549 cells, 1.735 µg/mL; NCI-H358 cells, 3.027 µg/mL; NCI-H1299 cells, 4.950 µg/mL. Then, 2×10^5 cells were collected and washed twice with phosphate-buffered saline (PBS). Apoptotic cells were detected with annexin V-fluorescein isothiocyanate/propidium iodide (FITC/PI) using an Annexin V-FITC Cell Apoptosis Detection Kit (BD Biosciences, Franklin Lakes, NJ, USA) according to the kit's protocol.

2.8. Statistical Analysis. The data are reported as the means \pm standard deviation (SD) and were analyzed using GraphPad Prism 5 (GraphPad Software Inc., La Jolla, CA, USA). All experiments were repeated at least three times. Groups were compared using Student's *t*-test or one-way analysis of variance (ANOVA). *P* < 0.05 was considered to indicate statistically significant difference.

3. Results

3.1. MiR-9 Expression Correlates Positively with NSCLC Cell Cisplatin Sensitivity. To research the relationship between




FIGURE 1: **Cisplatin sensitivity in NSCLC cells.** (a) CCK-8 determination of cell viability after treatment with 0, 0.3125, 0.625, 1.25, 2.5, or 5 µg/mL cisplatin. (b) RT-qPCR detection of miR-9 expression in cells. U6 was used as an internal control.

cisplatin sensitivity and miR-9 expression in NSCLC cells, CCK-8 was used to examine cell viability following a 48-hour treatment with 0, 0.3125, 0.625, 1.25, 2.5, or 5 µg/mL cisplatin. A549 cells were the most sensitive to cisplatin among the three NSCLC cell lines (median inhibitory concentration [IC50]: A549, 1.735 µg/mL; NCI-H358, 3.027 µg/mL; NCI-H1299; 4.950 µg/mL) (Figure 1(a)). Interestingly, A549 cells also had the highest miR-9 expression among the three cell lines (Figure 1(b)). These results indicate that miR-9 expression correlates positively with cisplatin sensitivity in NSCLC cells.

3.2. MiR-9 Regulates NSCLC Cell Cisplatin Sensitivity and Apoptosis. To determine whether miR-9 is related to cisplatin resistance in NSCLC cells, NSCLC cells were transfected with cisplatin alone or with cisplatin plus miR-9 mimic or inhibitor for 48 h, and then cell viability was detected using CCK-8. Figure 2(a) shows that compared with cisplatin alone, miR-9 mimic enhanced cisplatin sensitivity, while the miR-9 inhibitor decreased the effect of cisplatin in the cells. The EdU assay also proved that compared with cisplatin alone, miR-9 mimic could decrease the cell proliferation rate, while the miR-9 inhibitor had the opposite effect (Figures 2(b) and 2(c)). Flow cytometry showed that miR-9 mimic or miR-9 inhibitor increased the apoptosis rate compared with cisplatin alone (Figure 2(d)).

3.3. EIF5A2 Is a Direct Target Gene of miR-9 in NSCLC Cells. To further demonstrate whether miR-9 is involved in eIF5A2 expression, we used TargetScan (www.targetscan.org) to predict the relationship between miR-9 and eIF5A2 and found that EIF5A2 is a target gene of miR-9 (Figure 3(a)). RT-qPCR measurement of MIR9 and EIF5A2 mRNA expression showed that the A549 cells had the highest miR-9 expression but the lowest eIF5A2 expression among the NSCLC cell lines (Figures 3(b) and 3(c)), indicating that miR-9 correlates negatively with eIF5A2 expression. RT-qPCR and western blotting confirmed that compared with the negative control, miR-9

mimic could increase eIF5A2 mRNA and protein expression and that miR-9 inhibitor could decrease expression (Figures 3(d) and 3(e)).

3.4. EIF5A2 Knockdown Enhances NSCLC Cell Cisplatin Sensitivity. We used CCK-8 to detect cell viability following treatment with cisplatin with or without eIF5A2 siRNA and found that eIF5A2 knockdown significantly increased cisplatin sensitivity in the NSCLC cells (Figure 4(b)). The EdU assay was used to determine cell proliferation and showed that compared with the cisplatin alone group, cisplatin treatment plus eIF5A2 siRNA transfection reduced cell proliferation (Figure 4(c)). Western blotting demonstrated the interference efficiency of eIF5A2 (Figure 4(a)). These results demonstrate that inhibiting eIF5A2 significantly increases the cisplatin sensitivity of NSCLC cells.

3.5. MiR-9 Enhances NSCLC Cell Sensitivity to Cisplatin by Inhibiting eIF5A2 Expression. To verify whether miR-9 enhances NSCLC cell cisplatin sensitivity by regulating eIF5A2 expression, we silenced eIF5A2 and transfected the cells with miR-9 mimic or inhibitor before examining the cell viability via CCK-8. There was no significant difference among the three groups (Figures 5(d) and 5(f)). Western blotting detected the interference efficiency of eIF5A2 (Figures 5(a)–5(c)). These findings prove that miR-9 may increase NSCLC cell sensitivity to cisplatin by inhibiting eIF5A2 expression.

4. Discussion

Lung cancer is a major cause of cancer-related death worldwide. As a chemotherapy drug, cisplatin is used for extensive treatment in NSCLC, although cisplatin resistance presents a significant barrier to the improvement of the long-term outcome of patients with NSCLC [20, 21]. Many factors enhance the sensitivity of NSCLC cells to cisplatin and may reveal novel targets for therapy. Therefore, it is very




FIGURE 2: MiR-9 overexpression enhances NSCLC cell sensitivity to cisplatin. (a) CCK-8 examination of cell viability following treatment with cisplatin alone or with cisplatin plus miR-9 mimic or inhibitor. (b, c) EdU staining analysis of cell proliferation following treatment with cisplatin alone or with cisplatin plus miR-9 mimic or inhibitor. * $P < 0.05$, ** $P < 0.01$ vs. cisplatin; *** $P < 0.001$ vs. cisplatin+miR-9 mimic. (d) Flow cytometry determination of the percentage of apoptotic cells following treatment with cisplatin alone or with cisplatin plus miR-9 mimic or inhibitor. * $P < 0.05$, ** $P < 0.01$, and *** $P < 0.001$.

important to identify therapeutic targets to improve the cisplatin sensitivity of NSCLC cells.

MiRNAs play a crucial role in many biological processes, such as proliferation, apoptosis, and differentiation, by modulating gene expression at posttranscriptional level [22]. Aberrant miRNAs can affect the expression of target genes,

which may modulate cell death signaling pathways, drug target proteins, and cell cycle-related proteins. This may lead to cancer cell resistance to various therapies [23]. Numerous researchers have demonstrated that miRNAs could be a novel tool for cancer diagnostics and therapeutics [24]. For example, miR-1271 upregulation enhances cisplatin sensitivity in




FIGURE 4: EIF5A2 knockdown enhances NSCLC cell sensitivity to cisplatin. (a) Western blot shows decreased eIF5A2 levels following transfection with eIF5A2 siRNA as compared with negative siRNA. (b) CCK-8 showing decreased cell viability following transfection with eIF5A2 siRNA as compared to negative siRNA. (c) EdU staining determination of cell proliferation following treatment with cisplatin with and without eIF5A2 siRNA transfection. (d) Histogram representation of the EdU-positive cells. * $P < 0.05$ and ** $P < 0.01$ vs. negative siRNA.

repression, mRNA cleavage, or a combination of both, which occurs mostly through direct targeting of the 3'UTRs of mRNAs [17, 36]. In the present study, bioinformatics analysis confirmed that eIF5A2 is a functional target of miR-9 in NSCLC cells. miR-9 mimic transfection decreased eIF5A2 expression, but transfection with miR-9 inhibitor enhanced eIF5A2 expression, suggesting that *EIF5A2* is a target gene of miR-9 in NSCLC cells. We then detected miR-9 expression in three NSCLC cell lines and found that miR-9 expression was

the highest in A549 cells, which were also the most sensitive to cisplatin among the three cell lines. Furthermore, miR-9 levels correlated negatively with eIF5A2 expression. Silencing eIF5A2 revealed that there was no significant difference in cisplatin sensitivity with or without miR-9 mimic and inhibitor, suggesting that miR-9 regulates cisplatin sensitivity in NSCLC cells by downregulating eIF5A2.

In conclusion, this study demonstrates that miR-9 expression correlates with cisplatin sensitivity in NSCLC cells.




FIGURE 5: **MiR-9 enhances NSCLC cell sensitivity to cisplatin by inhibiting eIF5A2 expression.** (a–c) Western blot showing eIF5A2 expression after siRNA transfection. (d–f) CCK-8 measurement of cisplatin sensitivity following siRNA transfection with miR-9 mimic or inhibitor.

miR-9 overexpression decreases eIF5A2 and increases cisplatin sensitivity, but inhibiting miR-9 decreases cisplatin sensitivity. Taken together, these data indicate that miR-9 could be an important therapeutic biomarker for enhancing chemosensitivity to cisplatin treatment.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

All authors declare that they have no conflicts of interest.

Acknowledgments

This work was supported by the Natural Science Fund of Zhejiang Province, China [Grant no. LQ16H160002], the Advanced Key Scientific and Technological Programs of Ningbo, China [Grant no. 2012C5017], the Natural Science Fund of Ningbo, China [Grant nos. 2014A610272, 2016A610196], and Ningbo Health Branding Subject Fund (PPXK2018-01).

References

[1] R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2016,” *CA: A Cancer Journal for Clinicians*, vol. 66, no. 1, pp. 7–30, 2016.
 [2] L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, and J. Lortet-Tieulent, “Global cancer statistics, 2012,” *CA: A Cancer Journal for Clinicians*, vol. 65, no. 2, pp. 87–108, 2015.

[3] A. J. Chou and R. Gorlick, “Chemotherapy resistance in osteosarcoma: Current challenges and future directions,” *Expert Review of Anticancer Therapy*, vol. 6, no. 7, pp. 1075–1085, 2006.
 [4] A.-M. Florea and D. Büsselberg, “Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects,” *Cancers*, vol. 3, no. 1, pp. 1351–1371, 2011.
 [5] G. C. Shukla, J. Singh, and S. Barik, “MicroRNAs: Processing, Maturation, Target Recognition and Regulatory Functions,” *Molecule Cell Pharmacology*, vol. 3, pp. 83–92, 2011.
 [6] L. R. Corsini, G. Bronte, M. Terrasi et al., “The role of microRNAs in cancer: diagnostic and prognostic biomarkers and targets of therapies,” *Expert Opinion on Therapeutic Targets*, vol. 16, supplement 2, pp. S103–S109, 2012.
 [7] T. Yu, K. Liu, Y. Wu et al., “MicroRNA-9 inhibits the proliferation of oral squamous cell carcinoma cells by suppressing expression of CXCR4 via the Wnt/beta-catenin signaling pathway,” *Oncogene*, vol. 33, pp. 5017–5027, 2013.
 [8] S.-B. Tian, J.-C. Yu, Y.-Q. Liu et al., “MiR-30b suppresses tumor migration and invasion by targeting EIF5A2 in gastric cancer,” *World Journal of Gastroenterology*, vol. 21, no. 31, pp. 9337–9347, 2015.
 [9] J. L. Horsham, C. Ganda, F. C. Kalinowski, R. A. M. Brown, M. R. Epis, and P. J. Leedman, “MicroRNA-7: A miRNA with expanding roles in development and disease,” *The International Journal of Biochemistry & Cell Biology*, vol. 69, pp. 215–224, 2015.
 [10] Y. Ren, H. Zhu, C. Chi, F. Yang, and X. Xu, “MiRNA-139 regulates oral cancer Tca8113 cells apoptosis through Akt signaling pathway,” *International Journal of Clinical and Experimental Pathology*, vol. 8, no. 5, pp. 4588–4594, 2015.
 [11] X. Zhao, L. Yang, and J. Hu, “Down-regulation of miR-27a might inhibit proliferation and drug resistance of gastric cancer cells,” *Journal of Experimental & Clinical Cancer Research*, vol. 30, no. 1, article no. 55, 2011.

- [12] L. Guo, Y. Pu, Z. Han et al., "MicroRNA-9 inhibits ovarian cancer cell growth through regulation of NF-kappaB1," *FEBS Journal*, vol. 276, no. 19, pp. 5537–5546, 2009.
- [13] L. Zheng, T. Qi, D. Yang et al., "microRNA-9 Suppresses the Proliferation, Invasion and Metastasis of Gastric Cancer Cells through Targeting Cyclin D1 and Ets1," *PLoS ONE*, vol. 8, no. 1, Article ID e55719, 2013.
- [14] J. Wang, H. Zhao, D. Tang, J. Wu, G. Yao, and Q. Zhang, "Overexpressions of microRNA-9 and microRNA-200c in human breast cancers are associated with lymph node metastasis," *Cancer Biotherapy and Radiopharmaceuticals*, vol. 28, no. 4, pp. 283–288, 2013.
- [15] L. Zhu, H. Chen, D. Zhou et al., "MicroRNA-9 up-regulation is involved in colorectal cancer metastasis via promoting cell motility," *Medical Oncology*, vol. 29, no. 2, pp. 1037–1043, 2012.
- [16] G. Xu, H. Yu, X. Shi et al., "MicroRNA-9 regulates non-small cell lung cancer cell invasion and migration by targeting eukaryotic translation initiation factor 5A2," *American Journal of Translational Research*, vol. 14, no. 1, 2014.
- [17] C. Lu, Z. Shan, C. Li, and L. Yang, "MiR-129 regulates cisplatin-resistance in human gastric cancer cells by targeting P-gp," *Biomedicine & Pharmacotherapy*, vol. 86, pp. 450–456, 2017.
- [18] X. Fan, S. Zhou, M. Zheng, X. Deng, Y. Yi, and T. Huang, "MiR-199a-3p enhances breast cancer cell sensitivity to cisplatin by downregulating TFAM (TFAM)," *Biomedicine & Pharmacotherapy*, vol. 88, pp. 507–514, 2017.
- [19] K. J. Livak and T. D. Schmittgen, "Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method," *Methods*, vol. 25, no. 4, pp. 402–408, 2001.
- [20] D. H. Shin, Y.-J. Choi, and J.-W. Park, "SIRT1 and AMPK mediate hypoxia-induced resistance of non-small cell lung cancers to cisplatin and doxorubicin," *Cancer Research*, vol. 74, no. 1, pp. 298–308, 2014.
- [21] A. Chang, "Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC," *Lung Cancer*, vol. 71, no. 1, pp. 3–10, 2011.
- [22] N. Lynam-Lennon, S. G. Maher, and J. V. Reynolds, "The roles of microRNA in cancer and apoptosis," *Biological Reviews*, vol. 84, no. 1, pp. 55–71, 2009.
- [23] T. Zheng, J. Wang, X. Chen, and L. Liu, "Role of microRNA in anticancer drug resistance," *International Journal of Cancer*, vol. 126, no. 1, pp. 2–10, 2010.
- [24] S. Yu, X. Qin, T. Chen, L. Zhou, X. Xu, and J. Feng, "MicroRNA-106b-5p regulates cisplatin chemosensitivity by targeting polycystic kidney disease-2 in non-small-cell lung cancer," *Anti-Cancer Drugs*, vol. 28, no. 8, pp. 852–860, 2017.
- [25] M. Yang, X. Shan, X. Zhou et al., "miR-1271 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R, IRS1, mTOR, and BCL2," *Anti-Cancer Agents in Medicinal Chemistry*, vol. 14, no. 6, pp. 884–891, 2014.
- [26] C. Tian, M. J. You, Y. Yu, L. Zhu, G. Zheng, and Y. Zhang, "MicroRNA-9 promotes proliferation of leukemia cells in adult CD34-positive acute myeloid leukemia with normal karyotype by downregulation of Hes1," *Tumor Biology*, vol. 37, no. 6, pp. 7461–7471, 2016.
- [27] P. M. J. Clement, H. E. Johansson, E. C. Wolff, and M. H. Park, "Differential expression of eIF5A-1 and eIF5A-2 in human cancer cells," *FEBS Journal*, vol. 273, no. 6, pp. 1102–1114, 2006.
- [28] Q.-B. Meng, W.-M. Kang, J.-C. Yu et al., "Overexpression of eukaryotic translation initiation factor 5A2 (EIF5A2) correlates with cell aggressiveness and poor survival in gastric cancer," *PLoS ONE*, vol. 10, no. 3, Article ID e0119229, 2015.
- [29] J.-H. Luo, W.-F. Hua, H.-L. Rao et al., "Overexpression of EIF5A2 predicts tumor recurrence and progression in pTa/pT1 urothelial carcinoma of the bladder," *Cancer Science*, vol. 100, no. 5, pp. 896–902, 2009.
- [30] B. Lou, J. Fan, K. Wang et al., "N1-guanyl-1,7-diaminoheptane (GC7) enhances the therapeutic efficacy of doxorubicin by inhibiting activation of eukaryotic translation initiation factor 5A2 (eIF5A2) and preventing the epithelial-mesenchymal transition in hepatocellular carcinoma cells," *Experimental Cell Research*, vol. 319, no. 17, pp. 2708–2717, 2013.
- [31] W. Zhu, M.-Y. Cai, Z.-T. Tong et al., "Overexpression of EIF5A2 promotes colorectal carcinoma cell aggressiveness by upregulating MTA1 through C-myc to induce epithelial-mesenchymal transition," *Gut*, vol. 61, no. 4, pp. 562–575, 2012.
- [32] L.-R. He, H.-Y. Zhao, B.-K. Li et al., "Overexpression of eIF5A-2 is an adverse prognostic marker of survival in stage I non-small cell lung cancer patients," *International Journal of Cancer*, vol. 129, no. 1, pp. 143–150, 2011.
- [33] Y. Bao, Y. Lu, X. Wang et al., "Eukaryotic translation initiation factor 5A2 (eIF5A2) regulates chemoresistance in colorectal cancer through epithelial mesenchymal transition," *Cancer Cell International*, vol. 15, no. 1, 2015.
- [34] Y. Liu, R. Liu, P. Fu et al., "N1-guanyl-1,7-diaminoheptane sensitizes estrogen receptor negative breast cancer cells to doxorubicin by preventing epithelial-mesenchymal transition through inhibition of eukaryotic translation initiation factor 5A2 activation," *Cellular Physiology and Biochemistry*, vol. 36, no. 6, pp. 2494–2503, 2015.
- [35] G. Xu, H. Yu, X. Shi et al., "Cisplatin sensitivity is enhanced in non-small cell lung cancer cells by regulating epithelial-mesenchymal transition through inhibition of eukaryotic translation initiation factor 5A2," *BMC Pulmonary Medicine*, vol. 14, no. 1, 2014.
- [36] D. P. Bartel, "MicroRNAs: target recognition and regulatory functions," *Cell*, vol. 136, no. 2, pp. 215–233, 2009.